China Biosimilar Discount Expectations May Deter MNCs
This article was originally published in The Pink Sheet Daily
Payers and physicians in China are eager to embrace biosimilars despite a lack of regulatory and reimbursement avenues, global contact research organization ICON PLC notes in a recent study presented at ISPOR’s Asia conference .
You may also be interested in...
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
CanSino's adenovirus-based COVID-19 vaccine, along with another one from state-owned Sinopharm grab promot approvals in China as Beijing shipping millions of doses around the world.
While global vaccine heavyweights Merck & Co, Sanofi and GSK are so far not faring so well to successfully develop a vaccine for COVID-19, smaller players are stepping up. That's especially true for segmented markets such as China.